Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CYANOTECH CORPCYAN · Entity 8431 | CFO, VP Fin & Admin, Treasurer | July 29, 2024 | July 31, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CYANOTECH CORP
Report date July 29, 2024 · Filed July 31, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 4,678 |
Ending reported balance
After 2024-07-29 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-29 · Exercise / conversion · Acquired 1,747 · Balance 5,334 F1: Represents the conversion upon vesting of restricted stock units into common stock. Row 2 · 2024-07-29 · Tax withholding · Disposed 656 · Balance 4,678 F2: No stock was sold. On July 29, 2024, in connection with the vesting of 1747 shares of stock, the Company withheld a total of 656 shares to satisfy a payroll tax liability incident to such vesting. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,714 |
Reported balance
After 2024-07-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-29 · Exercise / conversion · Disposed 1,747 · Balance 5,714 F3: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F4: The restricted stock units vest as to 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the conversion upon vesting of restricted stock units into common stock.
F2: No stock was sold. On July 29, 2024, in connection with the vesting of 1747 shares of stock, the Company withheld a total of 656 shares to satisfy a payroll tax liability incident to such vesting.
F3: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock.
F4: The restricted stock units vest as to 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ALBANY MOLECULAR RESEARCH INC
Report date August 31, 2017 · Filed September 05, 2017
Section 16 reporting ended · disclosed 2017-09-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2017-08-31 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-08-31 · Grant · Acquired 4,993 · Balance 63,568 Row 2 · 2017-08-31 · Disposition to issuer · Disposed 63,568 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $16.70 · Expires 2025-02-17 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-08-31 · Disposition to issuer · Disposed 75,000 · Balance 0 F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $17.05 · Expires 2025-03-02 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-08-31 · Disposition to issuer · Disposed 19,078 · Balance 0 F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $15.77 · Expires 2026-02-04 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-08-31 · Disposition to issuer · Disposed 31,609 · Balance 0 F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $18.41 · Expires 2027-02-08 | Direct | 0 |
Reported balance
After 2017-08-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2017-08-31 · Disposition to issuer · Disposed 46,791 · Balance 0 F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration").
F2: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 29, 2024 Filed Jul 31, 2024 16:36 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionRestricted Stock Units · Derivative | 1,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-024130 · rdgdoc.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,714 Underlying: Common Stock · 1,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F4 · derivative.exercise_date: The restricted stock units vest as to 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest as to 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 16:36 UTC | CYANOTECH CORP CYAN · Entity 8431 | Tax withholdingCommon Stock | 656 | $0.56 | $367.36 |
DisclosureSEC source: 0001437749-24-024130 · rdgdoc.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,678 F2 · kind: No stock was sold. On July 29, 2024, in connection with the vesting of 1747 shares of stock, the Company withheld a total of 656 shares to satisfy a payroll tax liability incident to such vesting. Read SEC document |
| July 29, 2024 Filed Jul 31, 2024 16:36 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionCommon Stock | 1,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-024130 · rdgdoc.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 18:29 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionRestricted Stock Units · Derivative | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-011678 · rdgdoc.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,461 Underlying: Common Stock · 33 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F4 · derivative.exercise_date: The restricted stock units vest as to 1,747 shares on July 29, 2024; 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest as to 1,747 shares on July 29, 2024; 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 18:29 UTC | CYANOTECH CORP CYAN · Entity 8431 | Tax withholdingCommon Stock | 13 | $0.40 | $5.20 |
DisclosureSEC source: 0001437749-24-011678 · rdgdoc.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,587 F2 · kind: No stock was sold. On April 8, 2024, in connection with the vesting of 33 shares of stock, the Company withheld a total of 13 shares to satisfy a payroll tax liability incident to such vesting. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 18:29 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionCommon Stock | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-011678 · rdgdoc.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,600 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 10:48 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionRestricted Stock Units · Derivative | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004961 · rdgdoc.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,494 Underlying: Common Stock · 3,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F4 · derivative.exercise_date: The restricted stock units vest as to 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest as to 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 3,900 shares on February 16, 2025; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 10:48 UTC | CYANOTECH CORP CYAN · Entity 8431 | Tax withholdingCommon Stock | 1,465 | $0.44 | $644.60 |
DisclosureSEC source: 0001437749-24-004961 · rdgdoc.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,567 F2 · kind: No stock was sold. On February 16, 2024, in connection with the vesting of 3,900 shares of stock, the Company withheld a total of 1,465 shares to satisfy a payroll tax liability incident to such vesting. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 10:48 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionCommon Stock | 3,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-24-004961 · rdgdoc.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,032 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 15:12 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionRestricted Stock Units · Derivative | 1,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-021377 · rdgdoc.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,594 Underlying: Common Stock · 1,747 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F4 · derivative.exercise_date: The restricted stock units vest as to 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest as to 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 15:12 UTC | CYANOTECH CORP CYAN · Entity 8431 | Tax withholdingCommon Stock | 656 | $0.84 | $551.04 |
DisclosureSEC source: 0001437749-23-021377 · rdgdoc.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,132 F2 · kind: No stock was sold. On July 31 2023, in connection with the vesting of 1,747 shares of stock, the Company withheld a total of 656 shares to satisfy a payroll tax liability incident to such vesting. Read SEC document |
| July 31, 2023 Filed Aug 1, 2023 15:12 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionCommon Stock | 1,747 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-021377 · rdgdoc.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,788 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 14:56 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionRestricted Stock Units · Derivative | 34 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009815 · rdgdoc.xml · derivative · entry 4 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,341 Underlying: Common Stock · 34 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F5 · derivative.exercise_date: The restricted stock units vest as to 1,747 shares on July 29, 2023; 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. F5 · derivative.expiration_date: The restricted stock units vest as to 1,747 shares on July 29, 2023; 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 14:56 UTC | CYANOTECH CORP CYAN · Entity 8431 | GrantRestricted Stock Units · Derivative | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009815 · rdgdoc.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,375 Underlying: Common Stock · 100 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F4 · derivative.exercise_date: The restricted stock units vests as to 34 shares on April 6, 2023; 1,747 shares on July 29, 2023; 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. F4 · derivative.expiration_date: The restricted stock units vests as to 34 shares on April 6, 2023; 1,747 shares on July 29, 2023; 33 shares on April 6, 2024; 1,747 shares on July 29, 2024; 33 shares on April 6, 2025; 1,747 shares on July 29, 2025; and 34 shares on April 6, 2026, in each case subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 14:56 UTC | CYANOTECH CORP CYAN · Entity 8431 | Tax withholdingCommon Stock | 13 | $0.94 | $12.22 |
DisclosureSEC source: 0001437749-23-009815 · rdgdoc.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41 F2 · kind: No stock was sold. On April 6 2023, in connection with the vesting of 34 shares of stock, the Company withheld a total of 13 shares to satisfy a payroll tax liability incident to such vesting. Read SEC document |
| April 06, 2023 Filed Apr 10, 2023 14:56 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionCommon Stock | 34 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-009815 · rdgdoc.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock. Read SEC document |
| July 29, 2022 Filed Aug 2, 2022 15:58 UTC | CYANOTECH CORP CYAN · Entity 8431 | GrantRestricted Stock Units · Derivative | 5,241 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-018407 · rdgdoc.xml · derivative · entry 1 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,275 Underlying: Common Stock · 5,241 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F2 · derivative.exercise_date: The restricted stock units vest as to 34 shares on April 6, 2023; and 1,747 shares each on July 29, 2023, July 29, 2024 and July 29, 2025, in each case subject to the reporting person's continued service with the Company on the vesting date. F2 · derivative.expiration_date: The restricted stock units vest as to 34 shares on April 6, 2023; and 1,747 shares each on July 29, 2023, July 29, 2024 and July 29, 2025, in each case subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 15:21 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionRestricted Stock Units · Derivative | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-008579 · rdgdoc.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34 Underlying: Common Stock · 33 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one (1) share of Cyanotech Common Stock. F4 · derivative.exercise_date: The restricted stock units vest as to 34 shares on April 6, 2023, subject to the reporting person's continued service with the Company on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest as to 34 shares on April 6, 2023, subject to the reporting person's continued service with the Company on the vesting date. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 15:21 UTC | CYANOTECH CORP CYAN · Entity 8431 | Tax withholdingCommon Stock | 13 | $3.03 | $39.39 |
DisclosureSEC source: 0001437749-22-008579 · rdgdoc.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20 F2 · kind: No stock was sold. On April 6 2022, in connection with the vesting of 33 shares of stock, the Company withheld a total of 13 shares to satisfy a payroll tax liability incident to such vesting. Read SEC document |
| April 06, 2022 Filed Apr 8, 2022 15:21 UTC | CYANOTECH CORP CYAN · Entity 8431 | Exercise / conversionCommon Stock | 33 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-008579 · rdgdoc.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · CFO, VP Fin & Admin, Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Represents the conversion upon vesting of restricted stock units into common stock. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:50 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 46,791 | $3.34 Strike: $18.41 | $156,281.94 |
DisclosureSEC source: 0001638599-17-000881 · doc4_4939.xml · derivative · entry 6 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 46,791 shares Expires 2027-02-08 F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:50 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 31,609 | $5.98 Strike: $15.77 | $189,021.82 |
DisclosureSEC source: 0001638599-17-000881 · doc4_4939.xml · derivative · entry 5 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 31,609 shares Expires 2026-02-04 F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:50 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 19,078 | $4.70 Strike: $17.05 | $89,666.60 |
DisclosureSEC source: 0001638599-17-000881 · doc4_4939.xml · derivative · entry 4 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,078 shares Expires 2025-03-02 F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:50 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerOption to Purchase Common Stock · Derivative | 75,000 | $5.05 Strike: $16.70 | $378,750.00 |
DisclosureSEC source: 0001638599-17-000881 · doc4_4939.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 75,000 shares Expires 2025-02-17 F2 · derivative.exercise_date: Immediately prior to the effective time of the Merger, each AMRI stock option, whether or not vested and exercisable, that is outstanding and unexercised immediately prior to the effective time, was automatically canceled and converted into the right to receive an amount in cash (less any applicable tax withholdings) equal to the product obtained by multiplying (1) the excess, if any, of the Merger Consideration over the per share exercise price of such AMRI stock option, by (2) the aggregate number of shares of AMRI common stock that were issuable upon exercise or settlement of such AMRI stock option immediately prior to the effective time. Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:50 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Disposition to issuerCommon Stock | 63,568 | $21.75 | $1,382,604.00 |
DisclosureSEC source: 0001638599-17-000881 · doc4_4939.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated as of June 5, 2017, by and among Albany Molecular Research, Inc. ("AMRI"), UIC Parent Corporation ("UIC Parent"), and UIC Merger Sub, Inc. ("UIC Sub") (the "Merger Agreement"). The Merger Agreement provides that each share of AMRI common stock and each outstanding restricted stock unit automatically be canceled and converted into the right to receive $21.75 in cash, without interest and less any applicable withholding taxes (the "Merger Consideration"). Read SEC document |
| August 31, 2017 Filed Sep 5, 2017 16:50 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 4,993 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000881 · doc4_4939.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,568 Read SEC document |
| March 02, 2017 Filed Mar 6, 2017 16:10 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 361 | $14.52 | $5,241.72 |
DisclosureSEC source: 0001144204-17-012954 · v461186_4.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,575 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| February 17, 2017 Filed Feb 21, 2017 16:53 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 2,097 | $18.71 | $39,234.87 |
DisclosureSEC source: 0001638599-17-000212 · doc4_4559.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,936 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantOption to Purchase Common Stock · Derivative | 46,791 | $0.00 Strike: $18.41 | $0.00 |
DisclosureSEC source: 0001638599-17-000179 · doc4_4539.xml · derivative · entry 3 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,791 Underlying: Common Stock · 46,791 shares Expires 2027-02-08 F1 · derivative.exercise_date: Option is exercisable as to 1/4th of the shares annually on the anniversary date of the grant for each of the next four years. Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 7,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000179 · doc4_4539.xml · nonDerivative · entry 2 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,033 Read SEC document |
| February 08, 2017 Filed Feb 10, 2017 16:05 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | GrantCommon Stock | 9,506 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-17-000179 · doc4_4539.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,899 Read SEC document |
| February 04, 2017 Filed Feb 7, 2017 16:02 UTC | ALBANY MOLECULAR RESEARCH INC AMRI · Entity 173403 | Tax withholdingCommon Stock | 655 | $18.52 | $12,130.60 |
DisclosureSEC source: 0001638599-17-000156 · doc4_4514.xml · nonDerivative · entry 1 Ladin Felicia I · CIK 0001632868 · SVP, Treasurer & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,393 F1 · kind: Consists of shares withheld by Albany Molecular Research, Inc. in order to satisfy the minimum tax withholding obligation of the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.